Interferon beta-1b

Interferon beta-1b
Systematic (IUPAC) name
Human interferon beta
Clinical data
AHFS/Drugs.com Micromedex Detailed Consumer Information
MedlinePlus a601151
Pregnancy cat.  ?
Legal status  ?
Identifiers
CAS number 145155-23-3 Y
ATC code L03AB08
DrugBank BTD00078
KEGG D00746 N
ChEMBL CHEMBL1201563 N
Chemical data
Formula C908H1408N246O253S6 
Mol. mass 20011.0 g/mol
 N(what is this?)  (verify)

Interferon beta-1b (tradenames Betaferon, Betaseron (North America), Extavia and ZIFERON) is a drug in the interferon family used to treat the relapsing-remitting and secondary-progressive forms of multiple sclerosis (MS). It is approved for use after the first MS event. It is administered by sub-cutaneous injection and has been shown to slow the advance of the affliction as well as reduce the frequency of attacks.

It is believed that interferon-beta based drugs achieve their beneficial effect on MS progress via their anti-inflammatory properties. Studies have also determined that interferon-beta improves the integrity of the blood-brain barrier (BBB)—which generally breaks down in MS patients, allowing increasing amounts of undesirable substances to reach the brain. This strengthening of the BBB may be a contributing factor to interferon-beta's beneficial effects. These studies were carried out in vitro, so it does not necessarily mean it works the same in people.

Patients taking Interferon beta-1b may develop neutralizing antibodies to the medication.[1] Reference link

Betaferon/Betaseron is marketed today by Bayer HealthCare. The originator was Schering AG (Berlex in North America), now part of Bayer HealthCare. Novartis has also introduced Extavia, a new brand of interferon beta-1b, in 2009.

In 2010 ZIFERON (a new brand for interferon beta-1b) has also been brought in by Zistdaru Danesh Ltd.

Closely related is interferon beta-1a, also indicated for MS, and with a very similar drug profile.

See also

References

External links